Stoke Therapeutics, Inc. Initial Public Offering
Davis Polk advised the representatives of the underwriters in connection with the $163.3 million initial public offering of 9,074,776 shares of common stock of Stoke Therapeutics, Inc.,…
Experience
To find Davis Polk deals and cases of particular interest, select filters based on practice, industry, region, lawyer and keyword.
Filters
IDEAYA Biosciences, Inc. Initial Public Offering
Davis Polk advised the underwriters in connection with an initial public offering of 5,750,000 shares of common stock of IDEAYA Biosciences, Inc. at $10.00 per share (which includes the…
Applied Therapeutics, Inc. Initial Public Offering
Davis Polk advised the representatives of the several underwriters in connection with a $40 million initial public offering of common stock of Applied Therapeutics, Inc. Applied…
NGM Biopharmaceuticals, Inc. Initial Public Offering
Davis Polk advised the underwriters in connection with an initial public offering of 7,521,394 shares of common stock of NGM Biopharmaceuticals, Inc. at $16.00 per share, for gross proceeds…
TransMedics Group, Inc. Initial Public Offering
Davis Polk advised the representatives of the underwriters in connection with the $104.7 million initial public offering of 6,543,500 shares of common stock of TransMedics Group, Inc.,…
Turning Point Therapeutics, Inc. Initial Public Offering
Davis Polk advised the representatives of the several underwriters in connection with a $191.5 million initial public offering of common stock of Turning Point Therapeutics, Inc…
Davis Polk Advises ShockWave Medical, Inc. on Its $111.4 Million Initial Public Offering
Davis Polk advised ShockWave Medical, Inc. on its SEC-registered initial public offering of 6,555,000 shares of common stock for an aggregate price to the public of approximately $111.4…
Horizon Pharma Follow-On Offering
Davis Polk advised the underwriters in connection with the $345 million public offering of ordinary shares of Horizon Pharma plc. Horizon’s ordinary shares are listed on the NASDAQ Global…
Davis Polk Advises Roche on Its Acquisition of Spark Therapeutics
Davis Polk is advising Roche on its approximately $4.3 billion acquisition of Spark Therapeutics, Inc. The transaction, which is expected to be completed in the second quarter of 2019, has…
Pernix Enters into an Agreement for the Sale of Substantially All of Its Assets Subject to a Competitive Bidding Process and Files for Chapter 11
Davis Polk is advising Pernix Therapeutics Holdings, Inc. in connection with its restructuring under chapter 11 of the United States Bankruptcy Code, entry into a “stalking horse” asset…